Should I Buy MET? MET 2026 Analysis

Should You Buy MetLife Inc (MET) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

77.200

1 Day change

1.23%

52 Week Range

87.560

Analysis Updated At

2026/01/26

MetLife Inc. (MET) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock is currently facing negative financial performance, bearish technical indicators, and hedge fund selling pressure. While analysts maintain some positive sentiment with price targets above the current price, the lack of immediate positive catalysts and weak financial trends make it prudent to hold off on buying this stock right now.

Technical Analysis

The stock's MACD is negative (-0.405) and contracting, indicating bearish momentum. RSI is at 34.169, which is neutral but nearing oversold levels. The stock is trading below the pivot level (77.418) and close to the first support level (75.435), suggesting limited upside potential in the short term. Moving averages are converging, indicating no clear trend.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The high open interest put-call ratio suggests bearish sentiment, while the low option volume put-call ratio indicates some short-term bullish activity. Overall, the options data leans slightly bearish.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts maintain some optimism with price targets above the current price, ranging from $90 to $101, and positive commentary on the company's business diversification and shareholder returns.

Neutral/Negative Catalysts

Hedge funds are aggressively selling, with a 119,940.49% increase in selling activity over the last quarter. Q3 financials show significant declines in revenue (-6.08% YoY), net income (-35.84% YoY), and EPS (-32.60% YoY). Analysts have recently downgraded the stock, citing risks such as low new-money spreads, commercial mortgage loan risks, and weak forward guidance.

Financial Performance

In Q3 2025, MetLife reported a revenue drop to $17.375 billion (-6.08% YoY), net income drop to $818 million (-35.84% YoY), and EPS drop to $1.22 (-32.60% YoY). These declines indicate weak financial performance and potential challenges in maintaining profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have mixed views. While some maintain Buy or Outperform ratings with price targets between $90 and $101, others have downgraded the stock due to concerns about valuation, credit risks, and commercial real estate exposure. The consensus reflects cautious optimism but acknowledges significant risks.

12 Analyst Rating

Wall Street analysts forecast MET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MET is 95.25 USD with a low forecast of 84 USD and a high forecast of 108 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 76.260

Low

Averages

95.25

High

108

Current: 76.260

Low

Averages

95.25

High

108

Barclays

Overweight -> NULL

downgrade

$98 -> $90

AI Analysis

2026-01-08

Reason

Barclays

Price Target

$98 -> $90

AI Analysis

2026-01-08

downgrade

Overweight -> NULL

Reason

Barclays lowered the firm's price target on MetLife to $90 from $98 and keeps an Overweight rating on the shares. The firm is "cautiously optimistic" on life insurers heading into 2026, saying capital strength, cash flow, and consolidation offset headwinds like spread compression and technology spend. Barclays adjusted ratings and price targets as part of its 2026 outlook.

UBS

downgrade

$95 -> $94

2026-01-08

Reason

UBS

Price Target

$95 -> $94

2026-01-08

downgrade

Reason

UBS lowered the firm's price target on MetLife to $94 from $95.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MET

Unlock Now

MET Should I Buy

MET Should I Buy

Should You Buy MetLife Inc (MET) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch